Dupixent (dupilumab) is at the center of lawsuits alleging it caused or worsened cutaneous T-cell lymphoma (CTCL). Regeneron, Sanofi-Aventis U.S. LLC and Genzyme Corporation are the defendants. It is commonly prescribed for atopic dermatitis (eczema).
A federal panel centralized the cases as MDL No. 3180 in New Jersey federal court on June 4, 2026. A putative class action followed on July 17, 2026.
Plaintiffs say the makers did not warn adequately about the risk. No recall, settlement or verdict has been announced. The claims remain allegations, and none has been decided in court.
- Case or litigation name: In re Dupixent (Dupilumab) Products Liability Litigation
- Defendants: Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis U.S. LLC; Genzyme Corporation
- Court and docket number, when available: MDL No. 3180, U.S. District Court for the District of New Jersey (JPML order, page 1)
- MDL number, judge, and case count, when an MDL exists: MDL No. 3180, District of New Jersey, Judge Zahid N. Quraishi; 15 actions centralized and 7 potential tag-along actions (JPML order of June 4, 2026)
- Filing date: Federal lawsuits since 2025; JPML motion filed February 13, 2026; MDL created June 4, 2026
- Main allegations: Plaintiffs allege Dupixent caused, or accelerated a preexisting, cutaneous T-cell lymphoma and that the defendants did not adequately warn
- Products or people involved: Dupixent (dupilumab) users diagnosed with cutaneous T-cell lymphoma, and their spouses or survivors
Table Of Contents
Latest Dupixent Lawsuit Updates
July 17, 2026: Putative Class Action Filed in Maryland
On July 17, 2026, two plaintiffs filed a putative class action in federal court in Maryland. They allege Regeneron failed to warn that Dupixent causes or is linked to cutaneous T-cell lymphoma, according to Regeneron’s quarterly report [1].
June 4, 2026: Panel Creates MDL No. 3180
On June 4, 2026, the Judicial Panel on Multidistrict Litigation sent fifteen Dupixent actions to the District of New Jersey as MDL No. 3180 [2]. It assigned them to Judge Zahid N. Quraishi.
The litigation is named In re Dupixent (Dupilumab) Products Liability Litigation. The order also counted seven potential tag-along actions pending across twelve districts. The cases move together for coordinated pretrial proceedings.
February 13, 2026: Plaintiffs Ask the Panel to Consolidate Cases
On February 13, 2026, several plaintiffs asked the JPML to consolidate the federal Dupixent lawsuits, according to Regeneron’s quarterly report. They sought coordinated pretrial proceedings and made the request by motion.
April 6, 2024: JAAD Study Reports an Association with Lymphoma
On April 6, 2024, the Journal of the American Academy of Dermatology published online a West Virginia University cohort study of patients with atopic dermatitis who used dupilumab [3].
What Is Dupixent?
According to the FDA, Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist that was initially approved in the U.S. on March 28, 2017 [4].
The lawsuits involve cutaneous T-cell lymphoma (CTCL), a form of lymphoma. Plaintiffs allege that Dupixent caused it or accelerated a preexisting case.
Who May Be Affected?
Plaintiffs in MDL No. 3180 used Dupixent and were later diagnosed with cutaneous T-cell lymphoma. Others are spouses or survivors of such users. Your own facts decide if you qualify, and only an individual legal review can tell.
The panel noted that the plaintiffs who asked for it agree it should not include B-cell lymphoma, Hodgkin’s lymphoma or other non-T-cell lymphomas.
Whether other T-cell lymphomas can join was left open, because no plaintiff then alleged one. The panel said cases can be added later through conditional transfer.
Reported Injuries or Damages
Plaintiffs in the MDL allege cutaneous T-cell lymphoma, including death claims by survivors and loss claims by spouses. They also allege that the defendants did not adequately warn about it.
The JAAD study found an increased risk of CTCL in atopic dermatitis patients who used dupilumab (odds ratio 4.1003, 95% confidence interval 2.055-8.192). Risk was not increased for other cutaneous or lymphoid malignancies.
Lavin, Dusza and Geller of Memorial Sloan Kettering Cancer Center published “Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System” in the Journal of Investigative Dermatology in January 2025 [5].
Evidence to Preserve
Records that show how you used Dupixent and when you were diagnosed are the most useful evidence to keep:
- Prescription and pharmacy records that show when you used Dupixent
- Medical and pathology records for the lymphoma diagnosis
- Records of your eczema or atopic dermatitis treatment
- Dated photos of skin changes
- Injection pens or packaging you still have
- Messages with your doctors and the manufacturer
- Insurance and billing records
Keep the original documents. Do not delete messages or photos, even if they seem minor. Store copies in one safe place.
Filing Deadlines
State law sets filing deadlines, and they vary with where you live and when the diagnosis and injury happened. Some states start the clock at diagnosis.
A missed deadline can end a claim even if your evidence is strong. Ask a lawyer about the deadline that applies to you, and do it soon.
Potential Compensation
A Dupixent injury claim may seek medical expenses, lost income, and pain and suffering. In wrongful death claims, damages may include funeral costs and loss of companionship. Spouses may claim loss of consortium.
Compensation amounts vary by case. Past results do not guarantee future outcomes. Potential compensation also differs between patients and surviving family members.
Frequently Asked Questions
What Did the Defendants Ask for in the Dupixent Cases?
The defendants in the Dupixent cases asked the Panel to limit the proceedings to actions alleging CTCL as the injury. The Panel recorded that request in its order centralizing the cases.
Can You Sue for Dupixent Lymphoma?
You can sue for Dupixent lymphoma if the facts support a claim. Plaintiffs include patients, spouses and survivors. Some allege Dupixent accelerated a lymphoma they already had.
What Does the Research Say About Dupixent and CTCL?
The research on Dupixent and CTCL reports an association and not proof. The JAAD study drew on TriNetX patient records. No court has decided whether Dupixent causes the cancer.
Has Dupixent Been Recalled?
Dupixent has not been recalled. No recall of the drug has been announced. The lawsuits are product liability claims about an alleged lymphoma risk, and they are separate from any recall.
References
- https://www.sec.gov/Archives/edgar/data/0000872589/000087258926000025/regn-20260630.htm
- https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3180-Transfer_Order-5-26.pdf
- https://pubmed.ncbi.nlm.nih.gov/38588818/
- https://www.fda.gov/media/189534/download
- https://pubmed.ncbi.nlm.nih.gov/38945437/